{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:09Z","timestamp":1784547429618,"version":"3.55.0"},"reference-count":134,"publisher":"California Digital Library (CDL)","issue":"3","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WestJEM"],"DOI":"10.5811\/westjem.2020.1.45898","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T22:17:15Z","timestamp":1588717035000},"source":"Crossref","is-referenced-by-count":18,"title":["Oncologic Emergencies: Immune-Based Cancer Therapies and Complications"],"prefix":"10.5811","volume":"21","author":[{"given":"Brit","family":"Long","sequence":"first","affiliation":[{"name":"Brooke Army Medical Center, Department of Emergency Medicine, Fort Sam Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Brem","sequence":"additional","affiliation":[{"name":"University of California, Irvine Health, Division of Hematology\/Oncology, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Koyfman","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center, Department of Emergency Medicine, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"29705","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Dubbs SB. The latest cancer agents and their complications. Emerg Med Clin North Am. 2018;36:485-92.","DOI":"10.1016\/j.emc.2018.04.006"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Brahmer JR,\u00a0Lacchetti C,\u00a0Schneider BJ,\u00a0et al;\u00a0National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol.\u00a02018;36(17):1714-1768.","DOI":"10.1200\/jop.18.00005"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Haanen JBAG,\u00a0Carbonnel F,\u00a0Robert C,\u00a0et al;\u00a0ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.\u00a02017;28(suppl_4):iv119-iv142.","DOI":"10.1093\/annonc\/mdx225"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.","DOI":"10.1056\/NEJMoa1003466"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.","DOI":"10.1056\/NEJMoa1200690"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185-202.","DOI":"10.1146\/annurev-med-092012-112807"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Smith KA, Gilbride KJ, Favata MF. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature. 1980;287:853\u20135.","DOI":"10.1038\/287853a0"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984;223:1412\u20134.","DOI":"10.1126\/science.6367046"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485\u201392.","DOI":"10.1056\/nejm198512053132327"},{"key":"ref9","unstructured":"Negrier S,\u00a0Maral J,\u00a0Drevon M,\u00a0et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am.\u00a02000;6 Suppl 1:S93-8."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hryniewicki AT,\u00a0Wang C,\u00a0Shatsky RA,\u00a0et al. Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J Emerg Med.\u00a02018;55(4):489-502.","DOI":"10.1016\/j.jemermed.2018.07.005"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Simmons D, Lang E. The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors.\u00a0Cureus. 2017;9(10):e1774.","DOI":"10.7759\/cureus.1774"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pardoll DM.\u00a0The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer.\u00a02012;12:252\u2013264.","DOI":"10.1038\/nrc3239"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kroschinsky F, Stolzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89.","DOI":"10.1186\/s13054-017-1678-1"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207\u201312.","DOI":"10.1016\/j.coi.2011.12.009"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568\u201371.","DOI":"10.21417\/b7z59d"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kostine M, Chiche L, Lazaro E, et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): an emerging challenge. Rev Med Interne. 2017;38:513\u201325.","DOI":"10.1016\/j.revmed.2017.01.004"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Judd J, Zibelman M, Handorf E, et al. Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. Oncologist. 2017;22:1232\u20137.","DOI":"10.1634\/theoncologist.2017-0133"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.","DOI":"10.3389\/fphar.2017.00311"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Blumenthal GM, Pazdur R. Approvals in 2016: the march of the checkpoint inhibitors. Nat Rev Clin Onco.l 2017;14:131\u20132.","DOI":"10.1038\/nrclinonc.2017.15"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Peng TR,\u00a0Wu TW. Efficacy of PD-1\/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: a\u00a0meta-analysis\u00a0of randomized clinical trials. Thorac Cancer.\u00a02019;10(5):1176-81.","DOI":"10.1111\/1759-7714.13060"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Khan M1,\u00a0Lin J1,\u00a0Liao G1,\u00a0et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a\u00a0meta-analysis\u00a0of randomized controlled trials. Medicine (Baltimore).\u00a02018 Aug;97(33):e11936.","DOI":"10.1097\/md.0000000000011936"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","DOI":"10.1126\/science.aar6711"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","DOI":"10.1056\/NEJMra1706169"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","DOI":"10.1158\/2159-8290.cd-12-0548"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sadelain M, Brentjens R, Riviere I, et al. CD19 CAR therapy for acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2015:e360\u20133","DOI":"10.14694\/edbook_am.2015.35.e360"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.\u00a0Acta Pharm Sin B. 2018;8(4):539\u2013551.","DOI":"10.1016\/j.apsb.2018.03.001"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1. Blood. 2016;128(22):LBA-6-LBA-6.","DOI":"10.1182\/blood.v128.22.lba-6.lba-6"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Shibahara I, Saito R, Zhang R, et al. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol Cancer. 2015;14:41.","DOI":"10.1186\/s12943-015-0307-3"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen M, Wu Z, et al. CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies. J Clin Oncol. 2017;35(15_suppl):3042.","DOI":"10.1200\/jco.2017.35.15_suppl.3042"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Hegde M, Wakefield A, Brawley VS, et al. Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG). J Clin Oncol. 2014;32(15_suppl):10027.","DOI":"10.1200\/jco.2014.32.15_suppl.10027"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Hege KM, Bergsland EK, Fisher GA, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.","DOI":"10.1186\/s40425-017-0222-9"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Filley AC, Henriquez M, Dey M. CART Immunotherapy: development, success, and translation to malignant gliomas and other solid tumors.\u00a0Front Oncol. 2018;8:453.","DOI":"10.3389\/fonc.2018.00453"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Postow MA.\u00a0 Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book.\u00a02015;35:76\u201383.","DOI":"10.14694\/edbook_am.2015.35.76"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA.\u00a0Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol.\u00a02016;2:1346\u20131353.\u00a0","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Spain L, Diem S, Larkin J.\u00a0Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev.\u00a02016;44:51\u201360.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Postow MA, Sidlow R, Hellmann MD.\u00a0Immune-related adverse events associated with immune checkpoint blockade.\u00a0N Engl J Med. 2018;378:158\u2013168.","DOI":"10.1056\/nejmra1703481"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.\u00a0Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol.\u00a02017;35:785\u2013792.\u00a0","DOI":"10.1200\/jco.2015.66.1389"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Culakova E, Thota R, Poniewierski MS, et al.\u00a0Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med.\u00a02014;3:434\u2013444.","DOI":"10.1002\/cam4.200"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","DOI":"10.1056\/NEJMoa1200694"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018;36(4):638-46.","DOI":"10.1007\/s10637-017-0534-0"},{"key":"ref44","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560\u201375."},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.","DOI":"10.1186\/s12916-015-0455-8"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), 4.03. Bethesda, MD: National Institutes of Health; 2010.","DOI":"10.5152\/tud.2019.19133"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Champiat S, Lambotte O, Barreau E, et al.\u00a0\u00a0Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol.\u00a02016;27:559\u2013574.","DOI":"10.1093\/annonc\/mdv623"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373:1270\u20131.","DOI":"10.1056\/NEJMoa1504030"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Wu Y, Shi H, Jiang M, et al. The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety. Int J Cancer. 2017;141:2562\u201370.","DOI":"10.1002\/ijc.31012"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Lin Z, Chen X, Li Z, et al. PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis. PLoS One. 2016;11:e0160485.","DOI":"10.1371\/journal.pone.0160485"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","DOI":"10.1056\/NEJMoa1611299"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Naidoo J, Page DB, Li BT, et al.\u00a0Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol.\u00a02015;26:2375\u20132391.\u00a0","DOI":"10.1093\/annonc\/mdv383"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"El Majzoub I,\u00a0Qdaisat A,\u00a0Thein KZ, et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med.\u00a02019;73(1):79-87.","DOI":"10.1016\/j.annemergmed.2018.04.019"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","DOI":"10.1200\/jco.2012.41.6750"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Weber JS, Postow M, Lao CD, et al. Management of adverse events following treatment with anti-programmed death-1 agents.\u00a0Oncologist.\u00a02016;21:1230\u20131240.","DOI":"10.1634\/theoncologist.2016-0055"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ludlow SP, Kay N. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab. J Immunother. 2015;38:165\u20136.","DOI":"10.1097\/cji.0000000000000076"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors.\u00a0ESMO Open. 2017;2(4):e000247.","DOI":"10.1136\/esmoopen-2017-000247"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Wang DY, Okoye GD, Neilan TG, et al.\u00a0Cardiovascular toxicities associated with cancer immunotherapies.\u00a0Curr Cardiol Rep.\u00a02017;19:21.","DOI":"10.1007\/s11886-017-0835-0"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Johnson DB, Sullivan RJ, Menzies AM.\u00a0Immune checkpoint inhibitors in challenging populations.\u00a0Cancer.\u00a02017;123:1904\u201311.","DOI":"10.1002\/cncr.30642"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Jain D, Russell RR, Schwartz RG, et al.\u00a0Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions.\u00a0Curr Cardiol Rep. 2017;19:36.","DOI":"10.1007\/s11886-017-0846-x"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Eigentler TK, Hassel JC, Berking C, et al.\u00a0Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev.\u00a02016;45:7\u201318.","DOI":"10.1016\/j.ctrv.2016.02.003"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382.","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Naidoo J, Wang X, Woo K, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy.\u00a0J Clin Oncol. 2017;35(7):709-717.","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607\u201316.","DOI":"10.1001\/jamaoncol.2016.2453"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Suresh K, Naidoo J, Lin C, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities.\u00a0Chest. 2018;154(6):1416-1423.","DOI":"10.1016\/j.chest.2018.08.1048"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Nishino M, Chambers E, Chong C, et al. Anti-PD-1 Inhibitor-related pneumonitis in non-small cell lung cancer.\u00a0Cancer Immunol Res. 2016;4(4):289-293.","DOI":"10.1158\/2326-6066.cir-15-0267"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Divatia J, Khan P, Myatra S. Tracheal intubation in the ICU: life saving or life threatening?\u00a0Indian J Anaesth. 2011;55(5):470-475.","DOI":"10.4103\/0019-5049.89872"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Grover S, Rahma O, Hashemi N, Lim R. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management.\u00a0Am Soc Clin Oncol Educ Book. 2018;(38):13-19.","DOI":"10.1200\/edbk_100013"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Horvat TZ, Adel NG, Dang TO, et al.\u00a0Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.\u00a0J Clin Oncol.\u00a02015;33:3193\u20133198.","DOI":"10.1200\/jco.2015.60.8448"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200:W468\u201374.","DOI":"10.2214\/AJR.12.9751"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Pag\u00e8s C, Gornet JM, Monsel G, et al.\u00a0 Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res.\u00a02013;23:227\u2013230.\u00a0","DOI":"10.1097\/cmr.0b013e32835fb524"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Merrill SP, Reynolds P, Kalra A, et al.\u00a0 Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.\u00a0Ann Pharmacother.\u00a02014;48:806\u2013810.","DOI":"10.1177\/1060028014528152"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Belli C, Zuin M, Mazzarella L, et al. Liver toxicity in the era of immune checkpoint inhibitors: a practical approach.\u00a0Crit Rev Oncol Hematol. 2018;132:125-129.\u00a0","DOI":"10.1016\/j.critrevonc.2018.09.019"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Escandon J, Peacock S, Trabolsi A, et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.\u00a0J Immunother Cancer. 2017;5:3.","DOI":"10.1186\/s40425-016-0205-2"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors.\u00a0Br J Cancer. 2016;115(12):1457-1461.","DOI":"10.1038\/bjc.2016.358"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017; 377:1345-56.","DOI":"10.1111\/bjd.16785"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Yu C, Chopra IJ, Ha E.\u00a0A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep.\u00a02015;2015:140092.\u00a0","DOI":"10.1530\/edm-14-0092"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Martin-Liberal J, Furness AJS, Joshi K, et al.\u00a0\u00a0Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother.\u00a02015;64:765\u2013767.\u00a0","DOI":"10.1007\/s00262-015-1689-1"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Fellner A, Makranz C, Lotem M, et al.\u00a0Neurologic complications of immune checkpoint inhibitors.\u00a0J Neuro-Oncology.\u00a02018;137:601\u2013609.","DOI":"10.1007\/s11060-018-2752-5"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Astaras C, Michell R, Moura B, et al.\u00a0Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management.\u00a0Curr Neurol Neurosci Rep.\u00a02018;18:3.","DOI":"10.1007\/s11910-018-0810-1"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Hottinger AF.\u00a0Neurologic complications of immune checkpoint inhibitors.\u00a0Curr Opin Neurol.\u00a02016;\u00a029: 806\u2013812.","DOI":"10.1097\/wco.0000000000000391"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Wick W, Hertenstein A, Platten M.\u00a0Neurological sequelae of cancer immunotherapies and targeted therapies.\u00a0Lancet Oncol. 2016;\u00a017: e529\u2013e541.","DOI":"10.1016\/s1470-2045(16)30571-x"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Kao JC, Liao B, Markovic SN, et al.\u00a0Neurological complications associated with anti-programmed death 1 (PD-1) antibodies.\u00a0JAMA Neurol.\u00a02017;74:1216\u20131222.","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Gonzalez NL, Puwanant A, Lu A, et al.\u00a0Myasthenia triggered by immune checkpoint inhibitors: new case and literature review.\u00a0Neuromuscul Disord.\u00a02017;27:266\u2013268.","DOI":"10.1016\/j.nmd.2017.01.002"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Wilgenhof S, Neyns B.\u00a0Anti-CTLA-4 antibody-induced Guillain\u2013Barr\u00e9 syndrome in a melanoma patient.\u00a0Ann Oncol.\u00a02011;22:991\u2013993.","DOI":"10.1093\/annonc\/mdr028"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Spain L, Walls G, Julve M, et al.\u00a0Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.\u00a0Ann Oncol.\u00a02017;28:377\u2013385.","DOI":"10.1093\/annonc\/mdw558"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Yshii LM, Hohlfeld R, Liblau RS.\u00a0Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.\u00a0Nat Rev Neurol.\u00a02017;13(12):755\u2013763.","DOI":"10.1038\/nrneurol.2017.144"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.\u00a0Neurological adverse events associated with immune checkpoint inhibitors: review of the literature.\u00a0Eur J Cancer.\u00a02017;73:1\u20138.","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al.\u00a0Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.\u00a0Eur J Cancer.\u00a02016;60:210\u2013225.","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Davis EJ,\u00a0Salem JE,\u00a0Young A, et al. Hematologic complications of immune checkpoint Iinhibitors. Oncologist.\u00a02019;24(5):584-588.","DOI":"10.1634\/theoncologist.2018-0574"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Kong BY, Micklethwaite KP, Swaminathan S, et al. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26:202\u2013204.","DOI":"10.1097\/cmr.0000000000000232"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Nair R, Gheith S, Nair SG. Immunotherapy associated hemolytic anemia with pure red-cell aplasia. N Engl J Med. 2016;374:1096\u20131097.","DOI":"10.1056\/nejmc1509362"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Palla AR, Kennedy D, Mosharraf H et al. Autoimmune hemolytic anemia as a complication of nivolumab therapy. Case Rep Oncol. 2016;9:691\u2013697.","DOI":"10.1159\/000452296"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Helgadottir H, Kis L, Ljungman P et al. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol. 2017; 28:1672\u20131673.","DOI":"10.1093\/annonc\/mdx177"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Delanoy N,\u00a0Michot JM,\u00a0Comont T,\u00a0et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol.\u00a02019;6(1):e48-e57.","DOI":"10.3410\/f.734623445.793555861"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Shiuan E, Beckermann KE, Ozgun A, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:8.","DOI":"10.1186\/s40425-017-0210-0"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Inadomi K, Kumagai H, Arita S, et al. Bicytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report. Medicine (Baltimore). 2016;95:e4283.","DOI":"10.1097\/md.0000000000004283"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Cooling LL, Sherbeck J, Mowers JC, et al. Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: A new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. Immunohematology. 2017;33:15-21.","DOI":"10.21307\/immunohematology-2019-004"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med. 2011;365:1747-1748.","DOI":"10.1056\/nejmc1110923"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Lozier J. More on hemophilia A induced by ipilimumab. N Engl J Med. 2012;366:280-281.","DOI":"10.1056\/NEJMc1113863"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28:288\u2013294.","DOI":"10.1097\/cco.0000000000000296"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015 Aug 20;126(8):1048. Dosage error in article text].\u00a0Blood. 2014;124(2):188\u2013195.","DOI":"10.1182\/blood-2015-07-656918"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy.\u00a0J Hematol Oncol. 2018;11(1):121.","DOI":"10.1186\/s13045-018-0653-x"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al. Cytokine release syndrome.\u00a0J Immunother Cancer. 2018;6(1):56.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","DOI":"10.1056\/NEJMoa1709866"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","DOI":"10.1056\/NEJMoa1709919"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Santomasso BD, Park JH, Salloum D, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL). Cancer Discov. 2018;8(8):958\u2013971.","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Zhang L-N, Song Y, Liu D. CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J Hematol Onc. 2018;11(1):41.","DOI":"10.1186\/s13045-018-0593-5"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-888.","DOI":"10.1016\/j.bbamcr.2011.01.034"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Winkler U, Jensen M, Manzke O, et al. Cytokine release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-24.","DOI":"10.1182\/blood.v94.7.2217.419k02_2217_2224"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-7.","DOI":"10.1182\/blood-2016-07-730671"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","DOI":"10.1016\/s1525-0016(16)34841-9"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-70.","DOI":"10.2217\/imt-2016-0020"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226\u201333.","DOI":"10.1182\/blood-2012-01-400515"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","DOI":"10.1016\/s1525-0016(16)35779-3"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Hill JA, Li D, Hay KA, Green ML, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Blood. 2018;131(1):121-130.","DOI":"10.1182\/blood-2017-07-793760"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.","DOI":"10.1186\/s13045-018-0627-z"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","DOI":"10.1001\/jama.2016.0288"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Romero-Bermejo FJ, Ruiz-Bailen M, Gil-Cebrian J, et al. Sepsis-induced cardiomyopathy. Curr Cardiol Rev. 2011;7(3):163-183.","DOI":"10.2174\/157340311798220494"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Singh K, Carson K, Shah R, et al. Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy. Am J Cardiol. 2014;113(8):1420-1428.","DOI":"10.1016\/j.amjcard.2014.01.419"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20(3):129-147.","DOI":"10.1016\/0049-0172(90)90055-k"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.","DOI":"10.1172\/jci200318921"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Arkader R, Troster EJ, Lopes MR, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006;91(2):117-120.","DOI":"10.1136\/adc.2005.077446"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-79.","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","DOI":"10.1056\/NEJMoa1609783"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.","DOI":"10.1056\/nejmoa1215134"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224.","DOI":"10.1182\/blood.v94.7.2217.419k02_2217_2224"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Reagan JL, Fast LD, Safran H, et al. Cellular immunotherapy for refractory hematological malignancies. J Transl Med. 2013;11:150.","DOI":"10.1186\/1479-5876-11-150"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383","DOI":"10.1182\/blood-2008-03-077974"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18(6):733-743.","DOI":"10.1634\/theoncologist.2012-0483"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Mitchell CD, Richards SM, Kinsey SE, et al. Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-745.","DOI":"10.1111\/j.1365-2141.2005.05509.x"}],"container-title":["Western Journal of Emergency Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T04:12:12Z","timestamp":1666498332000},"score":1,"resource":{"primary":{"URL":"https:\/\/escholarship.org\/uc\/item\/8hm46787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":134,"issue-title":["WestJEM 21.3 May Issue"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.5811\/westjem.2020.1.45898","relation":{},"ISSN":["1936-900X"],"issn-type":[{"value":"1936-900X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,13]]}}}